BioMarin Announces Third Quarter 2015 Financial Results and Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
BioMarin Pharma (BMRN) Tops Q3 EPS by 5c; Raises Outlook
October 29, 2015 4:06 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.60), $0.05 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $208.9 million versus the consensus estimate of $216.61 million.
BioMarin Pharma sees FY2015 revenue of $880-900 million, versus prior guidance of $850-880 million and the... More
